Avalon GloboCare (NASDAQ:AVCO) Announces Initiation of First-in-Human Clinical Trial of Its CAR-T Candidate, AVA-001, for Treatment of B-Cell Malignancies
The clinical trial will interrogate the treatment of relapsed/refractory B-cell malignancies, including B-cell lymphoblastic leukemia (B-ALL) and non-Hodgkin's Lymphoma (NHL)
View full press release